The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., May. 29, 1:17 PM

Slide #3. Aerie Pharmaceuticals, Inc. Secondary Offering

Company: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)
Date announced: 5/25/2017
Secondary Offering Details: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock.

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Co.'s primary product candidate, Rhopressa™, is a once-daily eye drop designed to lower intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Co.'s second product candidate is once daily Roclatan™, a fixed-dose combination of Rhopressa™ and latanoprost, the most commonly prescribed drug for the treatment of patients with open-angle glaucoma.

AERI SEC Filing Email Alerts Service

Open the AERI Page at The Online Investor »

Company Name:  Aerie Pharmaceuticals Inc
Website:  www.aeriepharma.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding AERI:  23
Total Market Value Held by ETFs:  $112.03M
Total Market Capitalization:  $1.88B
% of Market Cap. Held by ETFs:  5.96%
 

Open the AERI Page at The Online Investor (in a new window) »

May 29, 2017    1:17 PM Eastern
Quotes delayed 20 minutes



Strong Buy (3.56 out of 4)
73rd percentile
(ranked higher than approx. 73% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2017, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.